Proteins

Product Data Sheet

MC-GGFG-Exatecan

Cat. No.: HY-114233 CAS No.: 1600418-29-8 Molecular Formula: $\mathsf{C}_{49}\mathsf{H}_{51}\mathsf{FN}_{8}\mathsf{O}_{11}$

Molecular Weight: 946.97


Target: Drug-Linker Conjugates for ADC; Topoisomerase

Pathway: Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

> In solvent -80°C 6 months

> > -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (52.80 mM; Need ultrasonic)


Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.0560 mL	5.2800 mL	10.5600 mL
	5 mM	0.2112 mL	1.0560 mL	2.1120 mL
	10 mM	0.1056 mL	0.5280 mL	1.0560 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) ^[1] .	
IC ₅₀ & Target	Camptothecins	
In Vitro	In MC-GGFG-Exatecan, GGFG is selectively cleaved by lysosomal enzymes (presumably cathepsins) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	In MC-GGFG-Exatecan, GGFG is known to release drugs into tumor tissue without releasing them into peripheral circulation [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

CUSTOMER VALIDATION



[1]. Nakada T, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1542-1545.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com